This inventor holds 1 USPTO granted patent. Top assignee: Medintell Biomed. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: The Innovations of Changjuan Xiang: A Breakthrough in Senile Dementia Treatment
Introduction: Changjuan Xiang, an innovative inventor based in Beijing, China, has made significant contributions to the field of medical research with his invention focused on senile dementia. With a growing concern over the increasing prevalence of this condition, Xiang’s work aims to provide effective diagnostic and therapeutic solutions.
Latest Patents: Changjuan Xiang holds a patent for a "Senile dementia treatment formulation and application thereof." This groundbreaking invention addresses the pressing need for molecular markers in diagnosing senile dementia. The formulation utilizes the ARHGAP11A gene, SPAG7 gene, and C16ORF7 gene, showcasing a novel approach to the treatment and diagnosis of this condition.
Career Highlights: Throughout his career, Xiang has demonstrated a commitment to advancing medical knowledge. His research includes high-throughput sequencing on peripheral blood samples of patients afflicted with senile dementia. By identifying genes that correlate well with the condition, he has laid a foundation for potential clinical applications in gene diagnosis.
Collaborations: Changjuan Xiang collaborates with esteemed colleagues, including Chenggang Yang and Feng Xiao, who share his dedication to innovation in medical treatments. Their collective efforts contribute to the ongoing research and development in addressing senile dementia.
Conclusion: Changjuan Xiang represents a beacon of hope in the fight against senile dementia. Through his innovative patent and collaborative research, he is paving the way for advancements in diagnosis and therapy, significantly impacting the lives of those affected by this condition. His work exemplifies the potential of targeted genetic research in developing effective medical treatments.